Objectives-To compare the efficacy and gastroduodenal safety of a fixed-dose combination of diclofenac sodium 50 mg and misoprostol 200 ,ig twice daily with those of piroxicam 10 mg twice daily and naproxen 375 mg twice daily in patients with osteoarthritis.
Methods-A 4 week, randomised, doubleblind, parallel-group, multicentre study was conducted in 643 patients with symptomatic osteoarthritis of the hip and/ or knee, who required continuous nonsteroidal anti-inflanmatory drug therapy for 4 weeks and who were without significant upper gastrointestinal damage as confirmed by endoscopy. Results-For patients who had pre-and post-treatment endoscopic examinations, gastroduodenal ulcers developed in 3 (1-50/) of 200 patients treated with diclofenac/misoprostol, 21 Misoprostol, a synthetic prostaglandin E, analogue, has been shown in controlled studies to prevent the development of NSAID-induced gastric and duodenal ulcers for periods of up to 1 year.'4 [18] [19] [20] Relative to other anti-ulcer agents, misoprostol has been found to be significantly more effective than ranitidine or sucralfate in the prevention of NSAID-induced gastric ulcers and comparable to ranitidine in preventing these ulcers in the duodenum. 2 Ethics and study design The study was designed as a randomised, double-blind, parallel-group multicentre trial lasting 4 weeks. Patients were randomised to receive diclofenac sodium 50 mg/misoprostol 200 ,g, piroxicam 10 mg, or naproxen 375 mg twice daily for 4 weeks.
All investigational drug supplies were provided by Searle (Skokie, Illinois, USA, or local Searle facility) and consisted of: plain white tablets containing diclofenac sodium 50 mg in a fixed combination with misoprostol 200 ,ug; plain white tablets containing placebo, identical in appearance to the fixed-combination tablets; unmarked gelatin capsules containing piroxicam 10 mg; unmarked gelatin capsules containing naproxen 375 mg; and unmarked gelatin capsules containing placebo, identical in appearance to both the piroxicam and naproxen capsules. To maintain 'blinding', all patients took one tablet and one capsule with the morning meal and one tablet and one capsule with the evening meal.
Compliance and patient evaluations Compliance was assessed by counting the number of tablets and the number of capsules returned at week 2 and week 4. Patients were also asked whether tablets and/or capsules were missed on more than two consecutive days.
During a pretreatment period (the 7 days immediately before the first dose of study medication), each patient provided a medical history, and physical and endoscopic examinations were performed. A blood sample was also taken from each patient and the following laboratory measurements were made: white blood cell count, haematocrit, haemoglobin, platelet count, creatinine, total bilirubin, alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase. In female patients of childbearing potential, a pregnancy test also was performed and confirmed as negative.
The endoscopy included examinations of the mucosa of the oesophagus, stomach, pyloric channel, and duodenum. The number of petechiae and erosions and the size of any ulcers were recorded. An erosion was defined as a lesion producing a definite break in the mucosa but without depth, and an ulcer was defined as a lesion with unequivocal depth.
The medical history included an estimate of the duration of osteoarthritis and various assessments of the current status of the disease including: (1) osteoarthritis severity index;26 (2) physician global assessment of arthritic condition;27 and (3) patient global assessment of arthritic condition. 28 The osteoarthritis severity index was based on patient responses to questions related to osteoarthritic pain, walking distance, and activities of daily living. The maximum possible index was 24. The physician and patient global assessments were both graded on a 5-point scale, where 1 =very good, 2 = good, 3 = fair, 4 = poor, and 5 = very poor. For the patient global assessment, the patient was asked to respond to the question: Considering all the ways your arthritis affects you, how are you doing today?
The treatment period was 4 weeks. The physical examination, clinical laboratory measurements, arthritis assessments, and endoscopic examination were repeated at the week 4 visit. In addition, any patient symptom was graded by the investigator as mild (causing no limitation of usual activities), moderate (causing some limitation of usual activities), or severe (causing inability to carry out usual activities).
Statistics
Chi square or Kruskal-Wallis nonparametric analyses were performed to determine whether patient randomisation had resulted in treatment groups that were comparable with respect to age, sex, height, weight, race, vital signs, baseline endoscopy scores, duration of osteoarthritis, and osteoarthritis assessments on admission.
All randomised patients were included in the analyses provided they had taken at least one dose of study medication (intention-to-treat cohort). The main end points were the proportion of patients with and without gastroduodenal, gastric, and duodenal ulceration and the number and porportion of patients whose assessments of osteoarthritis status were much improved (that is, decreased by at least two grades from baseline), improved (that is, decreased by 1 grade from baseline), much worse (that is, increased by at least 2 grades from baseline), worse (that is, increased by 1 grade from baseline), or unchanged at week 4. Chi square tests were used in the analysis of treatment group comparisons for all of these main end points, with the exception of the mean osteoarthritis severity index. Differences from baseline in the mean osteoarthritis index between treatment groups were compared using the Kruskal-Wallis test. Chi square analyses were performed on ulceration rates among patients who were less than 60 years of age versus those greater than or equal to 60 years of age.
All statistical testing was done using two-sided tests of significance at the 5% level.
Adverse event data were descriptively analysed. Shifts in laboratory test values also were compared within treatment groups using paired t tests and across treatment groups using chi square tests.
Results
A total of 643 patients were enrolled in the study. Of these, 216 were randomised to receive diclofenac sodium 50 mg/misoprostol 200 pug twice daily, 217 to receive piroxicam 10 mg twice daily, and 210 to receive naproxen 375 mg twice daily (intention to treat cohort). Table I shows that the three treatment groups were comparable with respect to age, sex, race, height, weight, and disease duration. Vital signs on admission, gastric and duodenal endoscopy scores, physician and patient global assessments of arthritic condition, functional capacity classification, and patient assessment of joint pain also were comparable among the treatment groups. A statistically significant treatment group difference was noted in the baseline osteoarthritis severity index (p = 0 024). (11) 30 (14) 32 (15) Of the 643 patients enrolled, 578 completed the study (193 (69-60/%) of those treated with piroxicam, and by 157 (74-8%) of those receiving naproxen. Adverse events affecting the gastrointestinal system were most common for each medication. The incidences of abdominal pain and diarrhoea were higher in the diclofenac/misoprostol group than in the piroxicam or naproxen groups (table  4) . However, 69% of the episodes of abdominal pain and 88% of the episodes of diarrhoea in the diclofenac/misoprostol group were mild or moderate in severity (table 5) .
Five patients (1, piroxicam; 4, naproxen) withdrew from the study after 4 to 18 days of treatment due to haematemesis or melaena. In three of these five patients (1, piroxicam; 2, naproxen), the source of the bleeding was gastroduodenal, as confinned by endoscopy. In one of the remaining patients treated with naproxen, endoscopy revealed oesophageal erosions as the source of bleeding. This patient was admitted to hospital and required a blood transfusion. The bleeding source could not be confirmed in the remaining patient treated with naproxen. Five laboratory measurements showed statistically significant changes from baseline values within the treatment groups. When the overall distribution of shifts (increase, decrease, or no change) in laboratory measurements were compared across treatment groups by chi square tests, only the shifts in alanine aminotransferase showed significant differences (p = 0 003).
Discussion
This study demonstrated that the fixed combination of diclofenac and misoprostol is associated with fewer gastroduodenal ulcers than either piroxicam or naproxen. The doses of diclofenac/misoprostol and naproxen used in this study were not the highest recommended adult doses but were in the range of doses recommended for treating the signs and symptoms of osteoarthritis. The 1/5% overall incidence of gastroduodenal ulcer with diclofenac/misoprostol found in this study of osteoarthritis patients is in agreement with incidences of 0-4% reported previously in patients with rheumatoid arthritis or osteoarthritis.23 24 The gastroduodenal ulceration rates for piroxicam and naproxen demonstrated in this study, 10 3% and 8-6%, respectively, indicate that these two widely prescribed nonsteroidal anti-inflammatory drugs have similar propensities for causing gastroduodenal ulcers and that a significant number of ulcers do develop during only 4 weeks of treatment.
Gastroduodenal ulcer development in this study was not dependent on the age of the patient. Younger patients (<60 years) were not at a lower risk of nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcer than were older patients (.60 years). Thus both younger and older patients treated with diclofenac/ misoprostol benefit from the mucosal protectant misoprostol.
Although inhibitor omeprazole protected the duodenum of healthy subjects from short-term NSAIDinduced damage, significant protection of the gastric mucosa was not demonstrated. 35 In contrast, the prostaglandin analogue misoprostol has been shown to significantly reduce the incidence of both gastric and duodenal ulcers in NSAID users.'4 [18] [19] [20] The adverse events found most frequently in this study were 24 The patients enrolled in our study are likely to be representative of the general population of patients with osteoarthritis using NSAIDs. Physicians now have a medication for treating patients, regardless of their age or sex, which is at least comparable to traditional NSAIDs for arthritis relief, but with approximately 85% fewer gastroduodenal ulcers.
